FDA Puts APB-102 Gene Therapy for SOD1 ALS on Fast Track
The U.S. Food and Drug Administration (FDA) has granted fast track status to Apic Bio’s experimental therapy APB-102, designed…
​​Vanda is a biochemist with a PhD in biomedicine from the University of Porto, Portugal. She conducted her postdoctoral research first at the Bristol Medical School, U.K., studying the insulin-PI3K/Akt signaling pathway in diabetic nephropathy, then at the Institute of Molecular Pathology and Immunology of the University of Porto, where her focus was on glycosylation in lupus nephritis and inflammatory bowel disease. She next made the switch to science publishing, handling papers in biochemistry, molecular biology, and immunology.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
The U.S. Food and Drug Administration (FDA) has granted fast track status to Apic Bio’s experimental therapy APB-102, designed…
Taking part in one Olympic event is an extreme accomplishment — but a U.K. couple are engaged in their version…
A £500,000 (almost $700,000) grant the My Name’5 Doddie Foundation was given to the LifeArc & MND Association Translational…
Amylyx Pharmaceuticals has raised $135 million to advance the clinical development and the potential launch of its lead candidate…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Prilenia’s pridopidine for the treatment of…
PharmaTher has filed an application with the U.S. Food and Drug Administration (FDA) requesting that ketamine be designated an…
The European Medicines Agency (EMA) has granted orphan drug designation to Seelos Therapeutics‘ investigational therapy SLS-005 for the treatment…